Imexpharm EBITDA Growth YoY
The Year-over-Year EBITDA Growth of Imexpharm (IMP.VN) as of Oct 26, 2026 is 11.10 %. In the previous year, Year-over-Year EBITDA Growth was 8.47 % — a change of 31.08% (higher).
Get this data via API
Financial Data API
EBITDA Growth YoY
11.10 %
YoY
31.08%
Last updated:
The Imexpharm EBITDA Growth YoY history
3 Years
10 Years
25 Years
Max
| YEAR | EBITDA Growth YoY | YoY |
|---|---|---|
| 11.10 % | +31.08% | |
| 8.47 % | -69.32% | |
| 27.59 % | +45.16% | |
| 19.01 % | -447.46% | |
| -5.47 % | -119.73% | |
| 27.73 % | +1.10% | |
| 27.43 % | +37.74% | |
| 19.91 % | +62.42% | |
| 12.26 % | +5.07% | |
| 11.67 % | +21.49% | |
| 9.60 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Imexpharm Stock analysis
Frequently Asked Questions about Imexpharm stock
Year-over-Year EBITDA Growth of Imexpharm is 11.10 % in 2025.
On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Imexpharm since 2006 – with annual values, charts, and detailed analysis.
EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.
To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.
Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Imexpharm historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Growth — Imexpharm
All Key Metrics — Imexpharm
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth